Dyadic International Inc. (NASDAQ: DYAI) reported growing interest in its C1 protein production platform as global health organizations respond to the ongoing Bundibugyo Ebola virus outbreak and the company advances commercial adoption across multiple markets.

The biotechnology company said its C1 platform can progress from receipt of a codon-optimized viral gene sequence to purified recombinant antigen or monoclonal antibody in approximately 15 days. The platform uses microbial manufacturing processes that the company says may support rapid vaccine and antibody production during infectious disease outbreaks.

Dyadic has initiated three tracks related to Ebola preparedness. The company announced a collaboration with Scripps Research to evaluate approaches for accelerating vaccine antigen and monoclonal antibody development for infectious diseases including Ebola and hantaviruses. The company also submitted research proposals in response to CEPI's Ebola funding call and is working on a monoclonal antibody initiative with Fondazione Biotecnopolo di Siena and the European Vaccines Hub.

"Recent outbreaks continue to demonstrate that speed matters," said Mark A. Emalfarb, Chief Executive Officer of Dyadic Applied BioSolutions. "Vaccines and antibody therapies that cannot be manufactured quickly, affordably and at sufficient scale are unable to reach the people who need them most."

Beyond pandemic preparedness, Dyadic reported commercial milestones including the launch of recombinant human albumin through Proliant Health & Biologicals, commercialization of recombinant DNase I through Fermbox Bio, and commercialization of recombinant bovine chymosin through Inzymes.

The company operates two protein production platforms: C1 for life sciences and biopharmaceutical applications, and Dapibus for food, nutrition, and industrial markets. Dyadic estimates these platforms target addressable market opportunities exceeding $25 billion across their respective sectors.